Epileptogenic drugs: A systematic review

Expert Review of Neurotherapeutics

Volumn 6, Issue 4, 2006, Pages 575-589

  Ruffmann, Claudio ^a   Bogliun, Graziella ^a,b   Beghi, Ettore ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Drug induced; Drugs; Epilepsy; Epileptogenic; Iatrogenic; Seizures

Indexed keywords

ALATROFLOXACIN; ALPHA INTERFERON; AMFEBUTAMONE; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CHLORAMBUCIL; CHLORPROMAZINE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLOMIPRAMINE; CLOZAPINE; CYCLOSPORIN; IMIPRAMINE; IODINATED CONTRAST MEDIUM; LEVOFLOXACIN; MAPROTILINE; MEROPENEM; MIDAZOLAM; NORFLOXACIN; NORPETHIDINE; OFLOXACIN; PENICILLIN DERIVATIVE; PETHIDINE; PROPOFOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEVOFLURANE; THIOPENTAL; UNINDEXED DRUG;

CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPILEPTIC DISCHARGE; EPILEPTIC STATE; GASTROINTESTINAL INFECTION; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHATIC LEUKEMIA; META ANALYSIS; MOOD DISORDER; NEUROTOXICITY; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SEXUALLY TRANSMITTED DISEASE; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; URINARY TRACT INFECTION;

EPILEPSY; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 33646806775     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.4.575     Document Type: Review

References (91)

1. Porter J, Jick M. Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms. Lancet 1(8011), 587-588 (1977).
2. Messing RO, Clausson RG, Simon RP. Drug-induced seizures: a 10-year experience. Neurology 34(12), 1582-1586 (1984).
3. De Lorenzo RJ, Hauser WA, Towne AR et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 46(4), 1029-1035 (1996).
4. Garcia PA, Allredge BK. Drug-induced seizures. Neurol. Clin. 12(1), 85-99 (1994).
5. Schlesselman JJ (Ed.). Case-control studies. Design, Conduct, Analysis. Oxford University Press, NY, USA (1977).
6. Ottman R. An epidemiologic approach to gene-environment interaction. Genet. Epidemiol. 7(3), 177-185 (1990).
7. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am. J. Ther. 9(1), 180-185 (2000).
8. Nadvi S, Sarnaik S, Ravindranath Y. Low frequency of meperidine- associated seizures in sickle cell disease. Clin. Pediatr. 38(8), 459-462 (1999).
9. Kaiko RF, Foley KM, Grabinski PY et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann. Neurol. 13(2), 180-185 (1983).
10. Modica PA, Tempelhoff R, White PF. Pro- and anticonvulsant effects of anesthetics (part II). Anesth. Analg. 70(4), 433-44 (1990).
11. Walder B, Tramèr MR, Seeck M. Seizure-like phenomena and propofol: a systematic review. Neurology 58(9), 1327-1332 (2002).
12. Yli-Hankala A, Vakkuri A, Sarkela M, Lindgren L, Korttila K, Jantti V. Epileptiform electroencephalogram during mask induction of anesthesia with sevoflurane. Anesthesiology 91(6), 1596-1603 (1999).
13. Vakkuri A, Jantti V, Sarkela M, Lindgren L, Korttila K, Yli-Hankala A. Epileptiform EEG during sevoflurane mask induction: effect of delaying the onset of hyperventilation. Acta Anaesthesiol. Scand. 44(6), 713-719 (2000).
14. Vakkuri A, Yli-Hankala A, Sarkela M et al. Sevoflurane mask induction of anaesthesia is associated with epileptiform EEG in children. Acta Anaesthesiol. Scand. 45(7), 805-811 (2001).
15. Nieminen K, Western-Punnonen S, Kokki H, Ypparila H, Hyvarinen A, Partanen J. Sevoflurane anaesthesia in children after induction of anaesthesia with midazolam and thiopental does not cause epileptoform EEG. Br. J. Anaesth. 89(6), 853-856 (2002).
16. Jaaskelainen SK, Kaisti K, Suni L, Hinkka S, Scheinin H. Sevoflurane is epileptogenic in healthy subjects at surgical levels of anaesthesia. Neurology 61, 1073-1078 (2003). • Epileptogenicity of studied drugs was accurately assessed by excluding possible confounding factors.
17. Lietman PS. Fluoroquinolone toxicities. An update. Drugs 49(Suppl. 2), 159-163 (1995).
18. O'Donnel JA, Gelone SP, Fluorquinolones. Infect. Dis. Clin. North Am. 14(2), 489-513 (2000).
19. Tack KJ, Smith JA. The safety profile of ofloxacin. Am. J. Med. 87(Suppl. 6c), 78-81(1989).
20. Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. Antimicrob. Agents Chemother. 38(3), 547-557 (1994).
21. Christie MJ, Wong K, Ting RH, Tam PY, Sikaneta TG. Generalized seizure and toxic epidermal necrolysis following levofloxacin exposure. Ann. Pharmacother. 39(5), 953-955 (2005).
22. Wong VK, Wright GT Jr, Ross LA et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr. Infect. Dis. J. 10(2), 122-125 (1991).
23. Koppel BS, Hauser WA, Politis C, van Duin D, Daras M. Seizures in the critically ill: the role of imipenem. Epilepsia 42(12), 1590-1593 (2001).
24. Eng RHK, Munsif AN, Yangco BG, Smith SM, Chmel H. Seizure propensity with imipenem. Arch. Int. Med. 149(8), 1881-1883 (1989).
25. Calandra G, Lydick E, Cardigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am. J. Med. 84(5), 911-918 (1988).
26. Schmutzard E, Williams KJ, Vukmirovits G et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J. Antimicrob. Chemother. 36(Suppl. A), 85-97 (1995).
27. Pestotnik SL, Classen DC, Evans RS, Stevens LE, Burke JP. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann. Pharmacother. 27(4), 497-501 (1993).
28. Brismar B, Malmborg AS, Tunevall G et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J. Antimicrob. Chemother. 35(1), 139-148 (1995).
29. Odio CM, Puig GR, Feris JM et al. Prospective, randomised, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Pediatr. Infect. Dis. J. 18(7), 581-590 (1999).
30. Wallace KL. Antibiotic-induced convulsions. Crit. Care Clin. 13(4), 741-762 (1997). • Gives a clear-cut picture of the mechanisms underlying the epileptogenic potential of antibiotics.
31. Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int. J. Antimicrob. Agents 11(2), 93-100 (1999).
32. Kamei C, Sunami A, Tasaka K. Epileptogenic activity of cephalosporins in rats and their structure-activity relationship. Epilepsia 24(4), 431-439 (1983).
33. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis. J. Antimicrob. Chemother. 27(4), 405-425 (1991).
34. Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am. J. Med. 100(6A), 68S-75S (1996).
35. Dunner DL, Zisook S, Billow AA et al. A prospective surveillance study for bupropion sustained-release in the treatment of depression. J. Clin. Psychiatry 59(7), 366-373 (1998).
36. Davidson J. Seizures and bupropion: a review. J. Clin. Psychiatry 50(7), 256-261 (1989). • Compares bupropion to its close relatives, thus giving a useful snapshot of the antidepressant family.
37. Settle EC, Stahl SM, Batey SR et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin. Ther. 21(3), 454-463 (1999).
38. Johnston JA, Lienberry CG, Ascher JA et al. A 102-center prospective study of seizure in association with bupropion. J. Clin. Psychiatry 52(11), 450-456 (1991). • One of the few articles that deals with a large sample.
39. Skowron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 12(1), 18-22 (1992).
40. Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression: a perspective on seizures. Arch. Gen. Psychiatry 43(1), 86-90 (1986).
41. Jabbari B, Bryan GE, Marsh EE, Gunderson CH. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch. Neurol. 42(5), 480-481 (1985).
42. Baumann PA, Maitre L. Neurobiochemical aspects of maprotiline (Ludiomil) action. J. Int. Med. Res. 7(5), 391-400 (1979).
43. Swinkels JA, de Jonghe F. Safety of antidepressants. Int. Clin. Psychopharmacol. 9(4), 19-25 (1995).
44. Lowry MB, Dunne FJ. Seizures during tricyclic therapy. Am. J. Psychiatry 137(11), 1461-1462 (1980).
45. Noyes R Jr, Garvey MJ, Cook BL, Samuelson L. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J. Clin. Psychiatry 50(5), 163-169 (1989).
46. Pisani F, Spina E, Oteri G. Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia 40(Suppl. 10), 48-56 (1999).
47. Dailey JW, Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem. Pharmacol. 52, 1323-1329 (1996).
48. Ebert U. Basic mechanisms of psychotropic drugs. Epilepsia 43(Suppl. 2), 2-7 (2002).
49. Ascher JA, Cole JO, Colin JN et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56, 395-401 (1995).
50. Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J. Pediatr. 93(3), 516-518 (1978).
51. Jourdan E, Topart D. Chlorambucil/prednisone-induced seizures in a patient with non-Hodgkin's lymphoma. Am. J. Hematol. 67(2), 147-149 (2001).
52. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 41(3), 369-371 (1991).
53. Sajatovic M, Meltzer HY. Clozapine-induced myoclonus and generalized seizures. Biol. Psychiatry 39(5), 367-370 (1996).
54. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5629 patients. Neurology 44(12), 2247-2249 (1994).
55. Kumra S, Frazier JA, Jacobsen LK, McKenna K. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch. Gen. Psychiatry 53(12), 1090-1097 (1996).
56. Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol. Psychiatry 42(2), 132-137 (1997).
57. Silvestri RC, Bromfield EB, Khoshbin S. Clozapine-induced seizures and EEG abnormalities in ambulatory psychiatric patients. Ann. Pharmacother. 32(11), 1147-1151 (1998).
58. Logothetis J. Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 17(9), 869-877 (1967).
59. Soucachet P, Dousinet P, D'Alteroche B. Manifestations cliniques comitiales au cours du traitement par la chlorpromazine. Rev. Neurol. 95(6), 566 (1956).
60. Szatmari A. Clinical and electroencephalogram investigation on largactil in psychosis (preliminary study). Am. J. Psychiatry 112(10), 788-794 (1956).
61. Lomas J, Boardman RH, Markowe M. Complications of chlorpromazine therapy in 800 mental-hospital patients. Lancet 268(6875), 1144-1147 (1955).
62. Schlichter W, Bristow ME, Schultz S, Henderson AL. Seizures occuring during intensive chlorpromazine therapy. Can. Med. Assoc. J. 74(5), 364-366 (1956).
63. Feldman PE. Clinical evaluation of chlorpromazine therapy for mental illness: analysis of one year's experience. J. Clin. Exp. Psychopath. 18, 1 (1957).
64. Bird EG, Goss JD Jr., Denber HCB. Chlorpromazine in the treatment of mental illness: a study of 750 patients. Am. J. Psychiatry 111(12), 930 (1955).
65. Kuztke JF. Seizures with promazine. Preliminary report. J. Nerv. Ment. Dis. 125 (1), 119-125 (1957).
66. Trimble M. The relationship between epilepsy and schizophrenia: a biochemical hypothesis. Biol. Psychiatry 12(2), 299-304 (1977).
67. Itil TM, Soldatos C. Epileptogenic side effects of psychotropic drugs. Practical recommendations. JAMA 244(13), 1460-1463 (1980).
68. Witten DM, Hirsch FD, Hartman GW. Acute reactions to urographic contrast medium: incidence, clinical characteristics and relationship to history of hypersensitivity states. Am. J. Roentgenol. Radium Ther. Nucl. Med. 119(4), 832-840 (1973).
69. Nelson M, Bartlett RJV, Lamb JT. Seizures after intravenous contrast media for cranial computed tomography. J. Neurol. Neurosurg. Psychiatry 52(10), 1170-1175 (1989).
70. LoZito JC. Convulsions: a complication of contrast enhancement in computerized tomography. Arch. Neurol. 34(10), 649-650 (1977).
71. Scott WR. Seizures: a reaction to contrast media for computed tomography of the brain. Radiology 137(2), 359-361 (1980).
72. Choi EJ, Kang JK, Lee SA, Kim KH, Lee SG, Andermann F. New-onset seizures after liver transplantation: clinical implications and prognosis in survivors. Eur. Neurol. 52(4), 230-236 (2004).
73. Wijkicks EFM, Plevak DJ, Wiesner RH, Steers JL. Causes and outcome of seizures in liver transplant recipients. Neurology 47(6), 1523-1525 (1996).
74. Bronster DJ, Emre S, Boccagni P, Sheiner PA, Schwartz ME, Miller CM. Central nervous system complications in liver transplant recipients - incidence, timing, and long-term follow-up. Clin. Transplant. 14(1), 1-7 (2000).
75. Erer B, Polchi P, Lucarelli G, Angelucci E et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. Bone Marrow Transplant. 18(1), 157-162 (1996).
76. Ghany AM, Tutschka PJ, McGhee RB et al. Cyclosporine-associated seizures in bone marrow transplant recipients given busulfan and cyclophosphamide preparative therapy. Transplantation 52(2), 310-315 (1991).
77. Trullemans F, Grignard F, Van Camp B, Schots R. Clinical findings and magnetic resonance imaging in severe cyclosporine-related neurotoxicity after allogenic bone marrow transplantation. Eur. J. Haematol. 67(2), 94-99 (2001).
78. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 24(1), 38-47 (1996).
79. Calvet MC, Gresser I. Interferon enhances the excitability of cultured neurons. Nature 278 (5704), 558-560 (1979).
80. Kunisaki TA, Augenstein WL. Drug- and toxin-induced seizures. Emerg. Med. Clin. North Am. 12(4), 1027-1053 (1994).
81. Bahls FH, Kelvin K, Bird TD. Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults. Neurology 41(1), 1309-1312 (1991).
82. Chin JH. Adenosine receptors in brain: neuromodulation and role in epilepsy. Ann. Neurol. 26(6), 276-279 (1989).
83. Weinstein RS. Recognition and management of poisoning with B-adrenergic blocking agents. Ann. Emerg. Med. 13(12), 1123-1135 (1984).
84. Zaccara G, Muscas GC, Messori A. Clinical features, pathogenesis and management of drug-induced seizures. Drug Saf. 5(2), 109-151 (1990). • Very useful article to gain an accurate overview of epileptogenic drugs.
85. Gasse C, Derby L, Vasiliskas-Scaramozza C, Jick H. Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy 20(6), 629-634 (2000).
86. Franson HL, Hay DP, Neppe V et al. Drug-induced seizures in the elderly. Causative agents and optimal management. Drugs Aging 7(1), 38-48 (1995).
87. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 39(1), 5-17 (1998).
88. Leber P. "Time-less" risks (a hazard of risk assessment: the example of seizure and antidepressants). Psychopharmacology Bull. 21(2), 334-338 (1985).
89. Hauser WA. Incidence and prevalence. In: Epilepsy: A Comprehensive Textbook. Engel J Jr, Pedley TA (Eds). Lippincot-Raven, PA, USA, 47-57 (1997).
90. Delanty N, Vaughan CJ, French JA. Medical causes of seizures. Lancet 352(9125), 383-390 (1998).
91. Annegers JF, Hauser WA, Lee JRJ, Rocca WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. Epilepsia 36(4), 327-333 (1995).